Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Companies Leadership

Novartis To Cut 8,000 Jobs In Global Restructure

Follows Through On Plan For Leaner Organization

  • News

Executive Summary

CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.

You may also be interested in...



Will CEO’s New Strategy Boost Roche’s Phase III Success?

Six months after taking the reins, Thomas Schinecker has unveiled a new approach aimed at preserving Roche’s 'R&D diversity' while cutting costly Phase III failures.

Novartis Appoints AbbVie Immunology Leader Horber To Succeed Tschudin

President of Innovative Medicines International and chief commercial officer Marie-France Tschudin will leave Novartis after nearly seven years.

After All The Layoffs, Is Biopharma’s Headcount Still Growing?

While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Generics Bulletin
Scrip
Scrip

Topics

Related Companies

Tags:
Commercial Companies Leadership
Latest Headlines

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

Pipeline Watch: Five Approvals And 23 Phase III Updates

Metsera Launches As New Obesity Contender Flush With $290m

See All
UsernamePublicRestriction

Register

SC146632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By